Immuneering Corporation's stock is experiencing a decline today, despite the company announcing a positive update from its Phase 2a arm studying IMM-1-104 in combination with modified FOLFIRINOX for first-line pancreatic cancer. The update, released on January 13, 2025, highlighted two additional partial responses, bringing the overall response rate to 50% among six evaluable patients. This is a significant improvement over the historic benchmark of 32% for FOLFIRINOX alone. Additionally, Immuneering strengthened its financial position by raising nearly $14 million through its ATM facility, which could support further clinical developments.
Despite these positive developments, the stock has not seen a corresponding upward movement. Immuneering's stock opened at $2.07 and has since decreased to $1.99 as of 10:00 AM on January 14, 2025. The stock has fluctuated between a high of $2.07 and a low of $1.97. Despite being just 30 minutes into the trading day, the volume is relatively low at 146,223 shares, representing only 6.05% of the average daily volume of 2,415,745 shares.